Strides Pharma Science Limited - Asset Resilience Ratio
Strides Pharma Science Limited (STAR) has an Asset Resilience Ratio of 3.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Strides Pharma Science Limited's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2026)
This chart shows how Strides Pharma Science Limited's Asset Resilience Ratio has changed over time. See Strides Pharma Science Limited (STAR) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Strides Pharma Science Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Strides Pharma Science Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.22 Billion | 3.2% |
| Total Liquid Assets | Rs2.22 Billion | 3.20% |
Asset Resilience Insights
- Limited Liquidity: Strides Pharma Science Limited maintains only 3.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Strides Pharma Science Limited Industry Peers by Asset Resilience Ratio
Compare Strides Pharma Science Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Strides Pharma Science Limited (2005–2026)
The table below shows the annual Asset Resilience Ratio data for Strides Pharma Science Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 3.20% | Rs2.22 Billion ≈ $23.97 Million |
Rs69.27 Billion ≈ $749.15 Million |
+1.78pp |
| 2025-03-31 | 1.42% | Rs860.59 Million ≈ $9.31 Million |
Rs60.49 Billion ≈ $654.15 Million |
-0.78pp |
| 2024-03-31 | 2.20% | Rs1.29 Billion ≈ $13.90 Million |
Rs58.40 Billion ≈ $631.55 Million |
+1.34pp |
| 2023-03-31 | 0.86% | Rs572.03 Million ≈ $6.19 Million |
Rs66.38 Billion ≈ $717.92 Million |
+0.67pp |
| 2022-03-31 | 0.19% | Rs134.55 Million ≈ $1.46 Million |
Rs69.76 Billion ≈ $754.41 Million |
-1.93pp |
| 2021-03-31 | 2.12% | Rs1.49 Billion ≈ $16.12 Million |
Rs70.15 Billion ≈ $758.65 Million |
-0.57pp |
| 2020-03-31 | 2.69% | Rs1.66 Billion ≈ $17.91 Million |
Rs61.52 Billion ≈ $665.29 Million |
-2.64pp |
| 2019-03-31 | 5.33% | Rs4.27 Billion ≈ $46.14 Million |
Rs80.06 Billion ≈ $865.77 Million |
-0.05pp |
| 2018-03-31 | 5.38% | Rs3.52 Billion ≈ $38.05 Million |
Rs65.44 Billion ≈ $707.68 Million |
-10.48pp |
| 2017-03-31 | 15.85% | Rs12.87 Billion ≈ $139.15 Million |
Rs81.17 Billion ≈ $877.80 Million |
+0.09pp |
| 2016-03-31 | 15.77% | Rs12.08 Billion ≈ $130.60 Million |
Rs76.59 Billion ≈ $828.30 Million |
-6.81pp |
| 2015-03-31 | 22.58% | Rs5.61 Billion ≈ $60.70 Million |
Rs24.86 Billion ≈ $268.86 Million |
+3.46pp |
| 2014-03-31 | 19.12% | Rs4.01 Billion ≈ $43.39 Million |
Rs20.99 Billion ≈ $227.00 Million |
+19.11pp |
| 2013-03-31 | 0.00% | Rs570.00K ≈ $6.16K |
Rs47.98 Billion ≈ $518.84 Million |
-8.31pp |
| 2012-03-31 | 8.31% | Rs4.54 Billion ≈ $49.13 Million |
Rs54.64 Billion ≈ $590.93 Million |
-11.36pp |
| 2011-03-31 | 19.67% | Rs8.84 Billion ≈ $95.60 Million |
Rs44.93 Billion ≈ $485.94 Million |
+14.25pp |
| 2010-03-31 | 5.42% | Rs1.75 Billion ≈ $18.93 Million |
Rs32.30 Billion ≈ $349.29 Million |
+0.02pp |
| 2009-03-31 | 5.40% | Rs1.26 Billion ≈ $13.60 Million |
Rs23.27 Billion ≈ $251.70 Million |
-1.12pp |
| 2008-03-31 | 6.52% | Rs1.33 Billion ≈ $14.34 Million |
Rs20.33 Billion ≈ $219.91 Million |
-0.81pp |
| 2007-03-31 | 7.34% | Rs900.11 Million ≈ $9.73 Million |
Rs12.27 Billion ≈ $132.69 Million |
+1.40pp |
| 2006-03-31 | 5.93% | Rs555.41 Million ≈ $6.01 Million |
Rs9.36 Billion ≈ $101.22 Million |
-2.57pp |
| 2005-03-31 | 8.51% | Rs465.09 Million ≈ $5.03 Million |
Rs5.47 Billion ≈ $59.12 Million |
-- |
About Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more